Please login to the form below
kidney disease
This page shows the latest kidney disease news and features for those working in and with pharma, biotech and healthcare.
AZ’s Farxiga cuts risk of death in chronic kidney disease
AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... It is often caused by diabetes, hypertension and
Latest news
-
Calliditas bets on PBC drug in Genkyotex buyout
The drug is also being evaluated in a phase 2 clinical trial in type 1 diabetes and kidney disease, and a further phase 2 trial of the drug in IPF is ... Genkyotex’s platform identifies small molecules which can selectively inhibit specific NOX enzymes
-
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial
Earlier this week, AZ also touted results for Farxiga in kidney disease, after the drug reduced kidney disease progression in a phase 3 trial of patients with chronic kidney disease ... In March, the US Food and Drug Administration (FDA) gave Jardiance
-
Gilead swoops on Forty Seven with $4.9bn all-cash deal
It also signed a $2.35bn deal with Nurix for protein degradation drugs for cancer and other diseases, and a $2bn alliance with Goldfinch Bio in the kidney disease area, continuing
-
Lilly’s Trulicity scores CV reduction indication in the US
a 15% decrease in the development of kidney disease compared to placebo. ... and without established cardiovascular disease," said Sherry Martin, vice president, medical affairs, Lilly.
-
Astellas files new application for expanded use of roxadustat in Japan
Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. . ... The standard treatment used to treat anaemia in people with chronic
More from news
Approximately 21 fully matching, plus 141 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD). ... Hypercholesterolemia is a major risk of
-
Case study: What we're made of
If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease. ... This could be a side effect of a condition such as stroke, motor neurone disease, multiple
-
25 Women Leaders in UK Healthcare
The firm has just signed a long-term collaboration with AZ for the discovery of new drugs for chronic kidney disease and idiopathic pulmonary fibrosis (IPF). ... disease and applying machine learning, artificial intelligence and collapsing analysis to
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
of JAK proteins is an established method of controlling the symptoms of this disease. ... The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
-
China: AstraZeneca’s new engine for growth and innovation
FibroGen in China for patients with anaemia in chronic kidney disease. ... AstraZeneca’s goal is to realise complete disease management, covering prevention, screening, diagnosis, treatment and follow- up.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Sanifit appoints Alexander Gold chief medical officer
Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Are biobetters a market access opportunity?
Mircera, used in the treatment of anaemia in Chronic Kidney Disease (CKD), was approved in 2007 by the European Medicines Agency (EMA) for once-monthly dosing as opposed to weekly dosing ... Ensuring market access for biobetters. Biobetters provide
-
Virtual Research Grants Submission and Approval Program
Our client’s main objectives were to:. Establish an independent review committee comprising experienced nephrologists and academics specializing in research related to kidney disease.
-
Addressing Climate Impact: The Healthcare Paradox
In 2018 there were 220 million more heatwave exposures affecting older populations increasing risks of heart and kidney stress and disease and stroke.
-
Its Know Your Numbers week
One in 4 adults in the UK has high blood pressure so the risk of developing heart disease, heart attacks, strokes, kidney disease and vascular dementia are very real. ... Lack of exercise. Being overweight. Chronic Kidney Disease. Regularly drinking
-
What are you doing, Dave?
parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- Lilly’s Verzenio scores a win in early-stage breast cancer
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
- Moderna’s COVID-19 vaccine generates strong immune response in older adults
- Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms
- What makes a great launch leader and launch team?
- The concordance conundrum: understanding the complexities of behaviour change
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
- The concordance conundrum: understanding the complexities of behaviour change
- Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
- The concordance conundrum: creating space for open dialogue
- Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Quick links
Infographics
